Citigroup raised its price objective and issued a buy rating for EyePoint Pharmaceuticals, which trades on Nasdaq.
3 reports, 2 independent
Updated Aug 19
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Citigroup raised its price objective and issued a buy rating for EyePoint Pharmaceuticals, which trades on Nasdaq.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.RBC adjusted its rating and Citigroup raised its price objective for EyePoint Pharmaceuticals.1 source
Citigroup issued a buy rating for EyePoint Pharmaceuticals stock.1 source
Keep exploring
The entities involved
-
EyePoint Pharmaceuticals (United Kingdom)
company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery
-
Citigroup
American investment bank and financial services corporation
Related events
- Citigroup raised its price target and gave a buy rating for International Paper, with MarketBeat providing consensus data.
- Citigroup raised its price target and gave a buy rating for Karman Holdings Inc.
- Citigroup lifted its price target and gave a buy rating for Timken Company, with MarketBeat providing consensus data.
- Citigroup restated a buy rating on shares of Intensity Therapeutics.
- Citigroup upgraded its target price and gave a buy rating for Fortrea.